It was studied clinically in the late 1960s and early 1970s, most notably in the treatment of advanced breast cancer, and was found to be effective, but was ultimately never marketed.
It was studied clinically in the late 1960s and early 1970s, most notably in the treatment of advanced breast cancer. The drug was found to be effective and showed weak androgenicity, but also produced severe signs of hepatotoxicity, and was ultimately never marketed.